2H0 Stock Chart & Stats
€4.08
€0.00(0.00%)
At close: 4:00 PM EST
€4.08
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€1.15 - €8.25
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€9.03M
Enterprise Value€24.54
Total Cash (Recent Filing)€2.60M
Total Debt (Recent Filing)€22.00K
Price to Earnings (P/E)―
Beta-1.70
Next Earnings
Aug 07, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.54
Shares Outstanding6,373,937
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.14
Price to Book (P/B)8.69
Price to Sales (P/S)0.00
P/FCF Ratio-3.99
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Board Refresh & Stronger Independent OversightThe board expansion and appointment of an independent director plus a formal Compensation Committee strengthen governance and oversight. Improved board composition is a durable control that can reduce operational and governance risk, improve strategic discipline and align executive incentives over the medium term.
Regained Nasdaq Compliance And Strategic Pipeline RefocusRegaining SEC/Nasdaq compliance removes immediate listing risk and restores investor transparency. Coupled with a declared strategic pivot toward hematologic indications and a lead stem-cell mobilization program, this represents a structural repositioning of R&D priorities that can sharpen value-creation pathways and partnerability.
Material Reduction In Leverage (zero Debt TTM)The elimination of reported debt materially lowers financial risk and interest obligations, improving flexibility to manage R&D cycles. With no TTM debt, the company can prioritize financing for operations or partnerships without near-term debt-servicing constraints, a durable balance-sheet improvement.
Bears Say
Sustained Negative Operating Cash FlowPersistent negative operating and free cash flow indicate ongoing cash burn with no internal self-funding. Over the next 2–6 months this necessitates external financing or asset sales, which can dilute shareholders or divert management focus from development and commercialization priorities.
Pre-revenue / Near-zero Revenue ProfileA $0 TTM revenue profile means the business lacks recurring commercial cash flows to offset R&D and G&A costs. This structural absence of revenue limits predictability, increases reliance on capital markets and partners, and reduces the company’s ability to demonstrate sustainable operating performance.
Eroding Equity Base And Sizable Net LossesThe sharp decline in equity alongside heavy net losses erodes the capital cushion that absorbs setbacks and funds development. A weakened equity base constrains financing options and increases the risk that future capital raises are dilutive or come on unfavorable terms, hampering long-term execution.
Exicure News
2H0 FAQ
What was Exicure’s price range in the past 12 months?
Exicure lowest stock price was €1.15 and its highest was €8.25 in the past 12 months.
What is Exicure’s market cap?
Exicure’s market cap is €9.03M.
When is Exicure’s upcoming earnings report date?
Exicure’s upcoming earnings report date is Aug 07, 2026 which is in 19 days.
How were Exicure’s earnings last quarter?
Exicure released its earnings results on May 13, 2026. The company reported -€0.251 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Exicure overvalued?
According to Wall Street analysts Exicure’s price is currently Overvalued.
Does Exicure pay dividends?
Exicure does not currently pay dividends.
What is Exicure’s EPS estimate?
Exicure’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Exicure have?
Exicure has 6,373,937 shares outstanding.
What happened to Exicure’s price movement after its last earnings report?
Exicure reported an EPS of -€0.251 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -5.344%.
Which hedge fund is a major shareholder of Exicure?
Currently, no hedge funds are holding shares in DE:2H0
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Exicure
Exicure, Inc. is a biotechnology firm that utilizes its unique spherical nucleic acid (SNA) platform to create therapies for neurological conditions and hair loss. Its primary experimental candidate, SCN9A, is currently undergoing preclinical evaluation for addressing neuropathic and chronic pain. The company has entered into a strategic partnership with AbbVie Inc. to advance SNA-based solutions for various hair loss conditions, under a collaboration, option, and license agreement. Additionally, a separate collaborative effort with Ipsen S.A. aims to investigate, develop, and commercialize novel spherical nucleic acids targeting Huntington's disease and Angelman syndrome. Established in 2011, Exicure's corporate base is located in Chicago, Illinois.